Mesoblast Limited (MESO) 20-F2022 FY Annual report (foreign)

Filed: 31 Aug 22, 6:02am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: aa, Accredited, adequacy, admission, AHA, alcohol, AlloVir, Alongside, AmerisourceBergen, Amplia, anonymously, answered, ARC, array, articulate, aspiration, backdrop, Baylor, Beach, Bell, Blueprint, bold, breaking, British, bullying, CGT, channel, CMO, Colon, commend, concessionary, Confronting, constantly, contact, conviction, coupled, CQA, creative, credentialed, CRL, CRO, CryoPort, CryoSite, CSM, darvadstrocel, dealt, decade, Depository, dialogue, dispersed, DNA, drawdown, DTA, ECCO, edge, embrace, Emerson, emphasize, energy, epidemic, ESG, ethnicity, evenly, excellence, Exit, falsification, finely, Finney, footing, foremost, formulaic, GL, GLP, graduated, green, GRI, guaranty, guardian, haematology, harassment, hard, headcount, hearing, hit, hitherto, holiday, holistic, honest, hostile, hotline, hsCRP, Hudson, huge, hybrid, IBD, ICF, ICH, ICS, ID, idea, immunocompromised, influenza, infrequently, inline, instilled, interview, intimidating, intimidation, intranet, irreversible, Jane, Krause, landmark, language, learning, Lightner, LLB, LLM, luminal, Macquarie, male, McDonald, mental, message, mildly, MilltechFX, mismatch, MOA, MOU, NRC, Oaktree, offensive, online, onsite, outsourced, Perin, Phi, Phillip, PI, predominantly, problem, prompt, prompted, pronounced, QA, quantifiable, quantified, Rectal, recycling, rehabilitation, religion, restraint, retaliation, Royal, runway, Russia, ruxolitinib, salvage, SASB, sexual, Showcase, socioeconomic, soluble, sound, spanning, surge, synergy, TAP, tasked, tightly, topic, TRIFR, tumorigenicity, turbulence, UC, Ukraine, unchanged, unintended, unvaccinated, upgraded, vacancy, vaccine, Vanderbilt, verbal, versed, veteran, victimization, vilification, viral, waste, wellbeing, wider, women, workplace, Yale, yellow

Removed: AABB, artery, BCT, benchmark, Biolife, BioSafe, blended, capped, capping, COBE, competitively, contrast, coronary, detected, dosed, Dundrum, earning, Electric, elevated, genetic, headquarter, hypertension, immunotherapy, ineligible, Inland, invoice, NMDP, positively, regimen, repurchase, retrospective, ruling, specialist, spouse, surrendered, Terumo, Thorney, weight

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated MESO transcripts

MESO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 13.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Mesoblast Limited (the “Company”) on Form 20-F for the year ended June 30, 2022 as filed on the date hereof (the “Report”) ”), I, Silviu Itescu, Chief Executive Officer for the Company, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: I, Silviu Itescu, certify that:

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 31, 2022	By:	/s/ Silviu Itescu
		Silviu Itescu
		Chief Executive Officer